News
EVMN
12.83
-3.50%
-0.47
Evommune’s EVO756 Migraine Trial: What Investors Should Know About This New Phase 2 Study
TipRanks · 4h ago
Evommune’s EVO756 Trial Completion Signals Key Milestone in Chronic Urticaria Market
TipRanks · 4h ago
Evommune's Healthy Balance Sheet Buys Them Time For AD
Seeking Alpha · 9h ago
Septerna price target lowered to $45 from $52 at Guggenheim
TipRanks · 10h ago
Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN) and Telix Pharmaceuticals (OtherTLPPF)
TipRanks · 19h ago
Evommune, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Evommune, Inc. (EVMN)
PR Newswire · 1d ago
Evommune Is Maintained at Overweight by Morgan Stanley
Dow Jones · 1d ago
Evommune Price Target Cut to $26.00/Share From $55.00 by Morgan Stanley
Dow Jones · 1d ago
Morgan Stanley Maintains Overweight on Evommune, Lowers Price Target to $26
Benzinga · 1d ago
This AAR Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday
Benzinga · 1d ago
Evommune price target lowered to $26 from $55 at Morgan Stanley
TipRanks · 1d ago
Evommune Cut to Neutral From Buy by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Downgrades Evommune to Neutral
Benzinga · 1d ago
Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN) and Palisade Bio (PALI)
TipRanks · 1d ago
Evommune price target lowered to $28 from $53 at Clear Street
TipRanks · 2d ago
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 2d ago
Evommune Cut to Market Perform From Outperform by William Blair
Dow Jones · 2d ago
William Blair Downgrades Evommune to Market Perform
Benzinga · 2d ago
Evommune's Skin Disorder Study Falls Short
Benzinga · 2d ago
Midday Fly By: SpaceX to join Nasdaq-100, Comcast to split into two companies
TipRanks · 2d ago
More
Webull provides a variety of real-time EVMN stock news. You can receive the latest news about EVOMMUNE INC through multiple platforms. This information may help you make smarter investment decisions.
About EVMN
Evommune, Inc. is a clinical-stage biotechnology company developing therapies that target key drivers of chronic inflammatory diseases. Its initial clinical development programs are focusing on chronic spontaneous urticaria (CSU), atopic dermatitis (AD) and ulcerative colitis (UC). Its product candidates include EVO756 and EVO301. The Company's advanced clinical-stage product candidate, EVO756, is a potent and highly selective oral small molecule antagonist of MRGPRX2, a receptor predominantly found on mast cells and peripheral sensory neurons, which is initially being evaluated in Phase II trials for the treatment of CSU and AD. The Company's second clinical-stage product candidate, EVO301, is a long-acting fusion protein consisting of an IL-18 binding protein (BP) and an anti-serum albumin Fab-associated (SAFA) domain, which is being evaluated in Phase II trials for the treatment of AD and UC.